A weekly summary of insider trading highlighting notable buying and selling by investors, directors and
Tilray Brands (NASDAQ:TLRY) shares snapped six straight sessions of losses, as the stock rose 1.9%
Amax Photo Tilray (NASDAQ:TLRY) reported positive results from a study of an oral cannabis extract
David Trood U.S.-listed cannabis stocks slipped in premarket trading on Wednesday after a costly campaign
Summary: I have been negative on Tilray Brands for quite some time and remain so.
Summary: Tilray’s Q1 revenue missed estimates by $21 million, showing 13% year-over-year growth driven by
strelov The upcoming U.S. presidential elections will likely bring about positive changes for the cannabis
Tilray press release (NASDAQ:TLRY): Q1 Non-GAAP EPS of -$0.01 beats by $0.02. Revenue of $200.04M